Viridian Therapeutics Reports Positive Phase 3 Results for Thyroid Eye Disease Treatment

Viridian Therapeutics (Nasdaq: VRDN) has announced positive topline data from its Phase 3 REVEAL-1 clinical trial for elegrobart. The trial evaluated the efficacy of the drug in patients with active thyroid eye disease (TED) using a subcutaneous delivery method. Elegrobart, a half-life-extended monoclonal antibody targeting the IGF-1R receptor, successfully met all primary endpoints in the study. This clinical milestone significantly de-risks the company's development pipeline and strengthens its path toward commercialization. The successful trial results are expected to support a future regulatory submission to the U.S. Food and Drug Administration (FDA). Market analysts view this development as a major positive catalyst for the company's stock performance and long-term growth prospects.